Neurotrophic Keratopathy Market to Witness Strong Growth and Significant Market Expansion by 2034 - DelveInsight

DelveInsight's report "Neurotrophic Keratopathy Market Insights, Epidemiology, and Market Forecast-2034," provides a comprehensive analysis of the Neurotrophic Keratopathy landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions.

Additionally, it examines Neurotrophic Keratopathy market dynamics, offering a thorough assessment of current and emerging market trends, treatment patterns, and therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom), and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives.

To Know in detail about the Neurotrophic Keratopathy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Neurotrophic Keratopathy Market Forecast
https://www.delveinsight.com/sample-request/neurotrophic-keratopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav

Some of the key facts of the Neurotrophic Keratopathy Market Report:
• The Neurotrophic Keratopathy market size was valued approximately USD 870 million in 2024 and is anticipated to grow with a significant CAGR during the study period (2020-2034).
• In May 2026, OXERVATE (cenegermin-bkbj) continued to be the sole FDA-approved treatment for neurotrophic keratitis in the United States, reinforcing its status as the leading biologic therapy for patients with moderate-to-severe disease.
• In April 2025, OKYO Pharma confirmed that urcosimod, previously known as OK-101, maintains stability for over two and a half years in single-use ampoules designed for patient use. This achievement marks a significant advancement in supporting the drug's long-term potential as it moves through clinical development. Urcosimod is currently undergoing a Phase 2b clinical trial a randomized, placebo-controlled, double-masked study with 48 participants-aimed at evaluating its efficacy in treating neurotrophic keratopathy (NCP), a severe and progressive degenerative eye condition.
• In 2024, the neurotrophic keratitis market in the US was valued at approximately USD 850 million and is projected to grow at a significant CAGR by 2034. The United States represented the largest share of the 7MM market, accounting for nearly 98% of the total, compared to other major markets including the EU4 (Germany, France, Italy, Spain), the UK, and Japan.
• Within the EU4 and UK, France held the largest market share at around 30%, while Germany recorded the smallest share at approximately 10% during the same year.
• According to DelveInsight research, there were roughly 140,000 prevalent cases of neurotrophic keratitis across the 7 major markets (7MM) in 2024, with projections indicating an increase by 2034.
• In Germany, prevalence was higher among females (around 3,650 cases) compared to males (approximately 2,400 cases), reflecting a greater disease burden in women, with overall cases expected to rise further. In the EU4 and the UK, about 60,300 people were living with neurotrophic keratitis in 2024, underscoring a significant regional disease burden and emphasizing the need for earlier diagnosis, better treatment options, and targeted strategies to prevent long-term corneal complications.
• In 2024, within the EU4 and the UK, the UK reported the highest number of diagnosed prevalent neurotrophic keratitis cases, at around 8,500, followed by Germany with approximately 6,000 cases. Spain had the lowest number, with about 3,400 cases.
• In the US, diagnosed cases showed a notable gender disparity, with females accounting for roughly 20,000 cases, significantly higher than the approximately 13,500 cases in males, highlighting a substantial gender-related disease burden.
• In 2024, Japan reported approximately 12,350 prevalent cases of neurotrophic keratitis, with numbers projected to increase by 2034, indicating a rising disease burden. Most cases were classified as Stage 3 (corneal ulcers), totaling around 2,500 cases, compared to nearly 1,950 cases in Stage 2 (persistent epithelial defects) and 1,110 cases in Stage 1 (epithelial alterations). This distribution underscores the higher burden of advanced disease and highlights the importance of early intervention to prevent progression.
• Key Neurotrophic Keratopathy Companies: Dompé Farmaceutici, BRIM Biotechnology, ReGenTree, LLC, Oyster Point Pharma, Inc., Syneos Health, Recordati Rare Diseases, MimeTech, Claris Biotherapeutics, and others
• Key Neurotrophic Keratopathy Therapies: OXERVATE (Cenegermin-bkbj), BRM424, RGN-259, OC-01 (varenicline), cenegermin-bkbj, Udonitrectag, rhNGF, REC 0559, CSB-001, and others
• The Neurotrophic Keratopathy epidemiology based on gender analyzed that most of the Neurotrophic Keratopathy cases comprise of the female population
• The Neurotrophic Keratopathy market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Neurotrophic Keratopathy pipeline products will significantly revolutionize the Neurotrophic Keratopathy market dynamics.

Neurotrophic Keratopathy Overview
Neurotrophic Keratopathy (NK) is a rare, degenerative eye disease caused by damage to the corneal nerves, leading to reduced corneal sensitivity. This loss of sensation impairs the cornea's ability to heal, resulting in persistent epithelial defects, corneal ulcers, and in severe cases, vision loss. Common causes include herpetic infections, diabetes, ocular surgeries, and neurological disorders. Early diagnosis and timely treatment are critical to prevent progression and preserve vision, often involving lubricating eye drops, therapeutic contact lenses, or novel regenerative therapies.

Get a Free sample for the Neurotrophic Keratopathy Market Report
https://www.delveinsight.com/report-store/neurotrophic-keratopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Neurotrophic Keratopathy Epidemiology
The Neurotrophic Keratopathy epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Neurotrophic Keratopathy Epidemiology Segmentation:
The Neurotrophic Keratopathy market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalent Cases of Neurotrophic Keratitis
• Total Diagnosed Prevalent Cases of Neurotrophic Keratitis
• Gender-Specific Diagnosed Prevalent Cases of Neurotrophic Keratitis
• Severity-Specific Diagnosed Prevalent Cases of Neurotrophic Keratitis

Download the report to understand which factors are driving Neurotrophic Keratopathy epidemiology trends @ Neurotrophic Keratopathy Epidemiology Forecast
https://www.delveinsight.com/sample-request/neurotrophic-keratopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav

Neurotrophic Keratopathy Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Neurotrophic Keratopathy market or expected to get launched during the study period. The analysis covers Neurotrophic Keratopathy market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Neurotrophic Keratopathy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Neurotrophic Keratopathy Therapies and Key Companies
• OXERVATE (Cenegermin-bkbj): Dompé Farmaceutici
• BRM424: BRIM Biotechnology
• RGN-259: ReGenTree, LLC
• OC-01 (varenicline): Oyster Point Pharma, Inc.
• cenegermin-bkbj: Dompé Farmaceutici
• Udonitrectag: Syneos Health
• rhNGF: Dompé Farmaceutici
• REC 0559: Recordati Rare Diseases/MimeTech
• CSB-001: Claris Biotherapeutics

Discover more about therapies set to grab major Neurotrophic Keratopathy market share @ Neurotrophic Keratopathy Treatment Market
https://www.delveinsight.com/sample-request/neurotrophic-keratopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav

Neurotrophic Keratopathy Market Drivers
• Increasing prevalence of corneal disorders, diabetes, ocular surgeries, and chronic eye surface diseases contributing to NK cases.
• Advancements in early diagnosis and improved awareness among ophthalmologists facilitating timely intervention.
• Introduction and adoption of novel therapies, such as recombinant human nerve growth factor (rhNGF), enhancing treatment outcomes.
• Strong clinical pipeline and ongoing R&D in regenerative therapies, biologics, and advanced wound-healing agents.
• Expanded healthcare infrastructure and reimbursement support improving patient access to advanced NK treatments.

Neurotrophic Keratopathy Market Barriers
• Limited awareness of NK in some regions leading to delayed diagnosis and treatment.
• High treatment costs, particularly for advanced biologics, restricting patient accessibility.
• Small patient population classified as orphan disease, limiting commercial incentives for major pharmaceutical companies.
• Complexity of disease management requiring specialized ophthalmology expertise.
• Regulatory challenges and long development timelines for novel therapies may slow market growth.

Scope of the Neurotrophic Keratopathy Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Neurotrophic Keratopathy Companies: Dompé Farmaceutici, BRIM Biotechnology, ReGenTree, LLC, Oyster Point Pharma, Inc., Syneos Health, Recordati Rare Diseases, MimeTech, Claris Biotherapeutics, and others
• Key Neurotrophic Keratopathy Therapies: OXERVATE (Cenegermin-bkbj), BRM424, RGN-259, OC-01 (varenicline), cenegermin-bkbj, Udonitrectag, rhNGF, REC 0559, CSB-001, and others
• Neurotrophic Keratopathy Therapeutic Assessment: Neurotrophic Keratopathy current marketed and Neurotrophic Keratopathy emerging therapies
• Neurotrophic Keratopathy Market Dynamics: Neurotrophic Keratopathy market drivers and Neurotrophic Keratopathy market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Neurotrophic Keratopathy Unmet Needs, KOL's views, Analyst's views, Neurotrophic Keratopathy Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.